Gemmer Asset Management LLC Takes $248,000 Position in Pfizer Inc. $PFE

Key Points

• Gemmer Asset Management LLC has acquired a stake worth approximately $248,000 in Pfizer Inc., totaling 10,231 shares, reflecting growing institutional interest in the biopharmaceutical company.
• Analysts have mixed views on Pfizer's stock, with reports indicating a recent price target increase from Citigroup and Morgan Stanley, but a downgrade from Wall Street Zen, resulting in an average rating of "Hold."
• Pfizer's recent earnings report showed an EPS of $0.78, exceeding expectations, and an annual revenue growth of 10.3%, leading to a positive FY 2025 guidance.

Gemmer Asset Management LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 10,231 shares of the biopharmaceutical company's stock, valued at approximately $248,000.

A number of other institutional investors and hedge funds also recently modified their holdings of PFE. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer during the 1st quarter worth about $27,000. North Capital Inc. purchased a new stake in shares of Pfizer during the 1st quarter worth about $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the 1st quarter worth about $28,000. Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the 1st quarter worth about $35,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer during the 1st quarter worth about $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on PFE shares. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a report on Saturday, September 27th. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Finally, Bank of America upped their price target on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $28.41.

Pfizer Stock Performance

Pfizer stock opened at $27.37 on Friday. The stock has a market cap of $155.59 billion, a P/E ratio of 14.56, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average of $24.67 and a 200-day moving average of $24.14. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.